It has been shown by Westerhof et al. that the ratio tau/T (where tau = Rp*SAC and Rp is total peripheral resistance, SAC is systemic arterial compliance, and T is heart period) is approximately a constant in all mammals under resting conditions such that diastolic pressure is sufficiently high to assure adequate coronary perfusion. The aim of this study is to determine if the ratio tau/T is constant under the transient condition of a rapid onset rate +Gz acceleration. We hypothesize that the ratio is held constant by the cardiovascular control system. Four male baboons were subjected to 10 second rapid onset +Gz profiles and aortic pressure and flow were recorded. Rp and C were calculated using a 2-element windkessel model and T was determined by the inverse of heart rate. All parameters were calculated on a beat-to-beat basis. It was found that the ratio increased very little at +2 Gz and increased dramatically at +3 and +5 Gz, disproving our hypothesis. This increase was due to large increases in peripheral resistance and changes in heart rate over the course of a Gz run. The increases are presumed to represent baroreceptor reflex response to the drop in aortic pressure experienced during +Gz stress. The ratio tau/T returned to its initial resting value shortly after the +Gz stressor was removed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Early-phase F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer's disease: a comparison with F-FDG-PET and early-phase amyloid-PET.
Eur J Nucl Med Mol Imaging
January 2025
Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Purpose: As dual-phase amyloid-PET can evaluate amyloid (A) and neurodegeneration (N) with a single tracer injection, dual-phase tau-PET might be able to provide both tau (T) and N. Our study aims to assess the association of early-phase tau-PET scans and F-fluorodeoxyglucose (FDG) PET and their comparability in discriminating Alzheimer's disease (AD) patients and differentiating neurodegenerative patterns.
Methods: 58 subjects evaluated at the Geneva Memory Center underwent dual-phase F-Flortaucipir-PET with early-phase acquisition (eTAU) and F-FDG-PET within 1 year.
The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease.
Brain Commun
December 2024
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona 08005, Spain.
CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and in cognitively unimpaired individuals. The CSF p-tau/Aβ42 ratio, a biomarker combining information from both pathophysiological processes, has emerged as a promising tool for monitoring disease progression, even at pre-clinical stages. Here, we studied the association between the CSF p-tau/Aβ42 ratio with downstream markers of pre-clinical Alzheimer's disease progression including brain structure, glucose metabolism, fibrillary Aβ deposition and cognitive performance in 234 cognitively unimpaired individuals, who underwent cognitive testing, a lumbar puncture, MRI, 18F-fluorodeoxyglucose and 18F-flutemetamol PET scanning.
View Article and Find Full Text PDFA fatal familial insomnia patient initially misdiagnosed as Alzheimer's disease: a case report.
BMC Neurol
December 2024
Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University, No.264, Guangzhou Road, Gulou District, Nanjing, Jiangsu, 210029, China.
Background: Fatal familial insomnia (FFI) is a rare autosomal dominant inherited disease and a type of prion diseases. We report a case of fatal familial insomnia (FFI) in a 52-year-old man who was initially misdiagnosed as Alzheimer's disease.
Case Presentation: The patient presented with persistent insomnia as the initial symptom, accompanied by cognitive impairment, autonomic dysfunction, and disorders of voluntary movement.
Associations between antidiabetic medications and cerebrospinal fluid biomarkers of Alzheimer's disease.
J Alzheimers Dis
December 2024
Research Group in Alzheimer Disease, Health Research Institute La Fe, Valencia, Spain.
Background: It has been hypothesized that insulin resistance is pivotal in mediating amyloid and tau dysregulations in Alzheimer's disease (AD).
Objective: To investigate the impact of different antidiabetic agents, their daily dosage intake, and treatment duration on cerebrospinal fluid (CSF) AD biomarkers among patients with type 2 diabetes.
Methods: This cross-sectional study selected patients between 50 and 80 years with diabetes and CSF AD biomarkers screened between 2017 and 2023 in the VALCODIS Cohort.
Cerebrospinal fluid tau and disease progression in early Parkinson's disease: an 8-year longitudinal study.
J Neurol
December 2024
Department of Neurology, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Chengdu, Sichuan, 610041, China.
Objective: To explore whether CSF phosphorylated tau-181 (P-tau181) and total tau (T-tau) are associated with disease progression in early PD patients.
Methods: We analyzed 8-year longitudinal clinical data from 368 early, drug-naive PD patients and 185 matched controls from the Parkinson's Progression Markers Initiative cohort. CSF P-tau181 and T-tau were measured over 5 years, while CSF α-synuclein was measured over 3 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!